# Genetic Signatures Investor Update – July 2017



## Disclaimer

This presentation was prepared by Genetic Signatures Limited known as "Genetic Signatures", ("GSS" or "the Company"), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange Limited ("ASX").

This presentation contains statements that involve estimates, risks and uncertainties. Although the Company believes these statements to be reasonable at this time, Genetic Signatures can give no guarantee that the expectations reflected in these statements will prove to be accurate. Actual results could differ materially from those expected for any of a multitude of risks including, but not limited to, those inherent in regulatory or market environments or more generally. In preparing this presentation, the Company has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources, or which was otherwise reviewed by it.

The presentation is proprietary to Genetic Signatures and may not be disclosed to any third party or used for any other purpose without the prior written consent of the Company.

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction and does not and will not form part of any securities subscription, purchase or sale contract.





## **Company Overview**

- Genetic Signatures Limited (GSS) designs and manufactures proprietary molecular diagnostic (MDx) test solutions for rapid and specific identification of diseases and infections
- GSS fully owns its proprietary molecular 3base<sup>™</sup> technology with multiple patents issued, expiring in 2031
- EasyScreen<sup>™</sup> products have an estimated US\$2.1B addressable global market in 2017
- Large pipeline of new molecular diagnostic tests to quickly drive further revenues and shareholder value
- Targeting pathology and hospital laboratories in multiple global markets leading to a scalable business with high gross margins
- Experienced management team and board with track record in global molecular diagnostics industry and delivering shareholder returns



## **Commercial Progress**

- June quarter Sales revenue growth of 16% on the previous corresponding period
- \$13.2M cash as of 30 June 2017
- Growing global profile through participation at EU, AU and US industry events coincides with offshore expansion
- New sales and marketing appointment supports overall strong foundation for future growth
- Completion of oversubscribed \$15M capital raising in September allowing for further investment in offshore expansion



## **Product Progress**

- Successful launch of new *3base*<sup>™</sup> *EasyScreen*<sup>™</sup> STI detection kit: global addressable STI testing market estimated at US\$550M in 2017
- First sale and delivery of beta-release 3base™ EasyScreen™ Flavivirus and Alphavirus detection kit
- First product trial of new *3base*<sup>™</sup> *EasyScreen*<sup>™</sup> Extended Spectrum Beta-Lactamase (ESBL) and Carbapenemase-producing organisms (CPO) Detection Kit for rapid antibiotic resistance detection of bacteria such as *E.coli* and *Klebsiella*
- Full EU regulatory approval for complete enteric suite allows unrestricted sales in 22% of global molecular diagnostics market
- 3base<sup>™</sup> patent approval in US where focus is on completing scientific validation for FDA product approval





## *EasyScreen*<sup>™</sup> STI Detection Kit Progress

- Successful launch of 3base<sup>™</sup> EasyScreen<sup>™</sup> Sexually Transmitted Infection (STI) Detection Kit — simultaneously detects the 12 most commonly encountered STIs and has superior multiple infection detection over existing hospital testing techniques
- First commercial customer secured SydPath, a fully accredited private Pathology Lab of St. Vincent's hospital in Sydney will use the new STI Kit on an ongoing basis
- Potential market 1 million people contracting an STI daily (World Health Organisation)





## *EasyScreen*<sup>™</sup> Flavivirus Detection Kit Progress

- GSS exhibited at the 27<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases in April — Highlighting the improved detection of Flaviviruses with GSS' *3base*<sup>™</sup> technology following a successful Vanuatu Dengue Detection Clinical Trial with Port Villa Central Hospital
- Results demonstrate strong performance The success of the trial shows the global potential of the 3base<sup>™</sup> EasyScreen<sup>™</sup> Flavivirus and Alphavirus Detection Kit to aid in preventing the spread of disease, including Zika and West Nile
- First commercial customer secured Ahead of product launch first significant offshore customer using beta-release on a trial basis
- Potential market Flavivirus' and Alphavirus' cause widespread morbidity and mortality in developed and developing world





## **Upcoming Activities**

- Focus remains on sales growth, product range expansion and market share expansion
- New global product trials underway or commencing this quarter
- Research and development on new kits and assays continues, including kits for atypical respiratory infections, antibiotic resistance and meningitis
- Preparation of two new products for commercial release (Flavirus and ESBL/CPO)
- GSS continues to work on securing regulatory approvals for STI and respiratory products whilst ongoing regulatory developments in the \$1.26B US market remain on course







## **Corporate Summary**

Financial Information (A\$)	
ASX Code	GSS
Shares on Issue	104.6M
Market Capitalisation	\$45M
Share Price (at market close 25 July 2017)	\$0.43
Cash at 30 June 2017	\$13.2M

Top Shareholders	%
Asia Union Investment Pty Limited	35.4%
Citicorp Nominees Pty Ltd	16.2%
UBS Nominees Pty Ltd	6.5%
Directors, Management and Advisors	>6.0%





# **Genetic Signatures** Transforming Global Molecular Diagnostics





## Genetic Signatures - 3Base™ Technology


### A transformational MDx technology enabling customers to identify a wider array of patient infections

- GSS' 3Base<sup>™</sup> platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variation between subtypes
- Patented chemical transformation of DNA and RNA sequences to reduce genetic code complexity
- Significant reduction in complexity and enhanced detection of multiplexed assays - multiple targets are detected in one tube





## Unique 3Base<sup>™</sup> Technology



- GSS' unique platform technology converts original 4-base microbial genome to 3-base, thereby reducing complexity in molecular testing
- Applicable in testing for infectious diseases and chronic diseases including cancers
- The conversion occurs during standard procedures and there are no additional steps for the end user
- 3Base<sup>™</sup> delivers greater sensitivity and specificity in a rapid assay





## Technology - 3Base™

- Massive reduction in complexity
- e.g, a 10 digit number comprised of the numbers 1,2,3 and 4 has **1,048,576 combinations**
- a 10 digit number comprised of the numbers 1,2 and 3 has **59,049 combinations**
- Reduces complexity by 97% yet maintains or increases accuracy

	Be	efor			1																		Af	ter	٦																	
Seq 1	G	А	Ţ		G	G	<u>C</u>	G	A	I	A	T	G	à (	G	Т	Ι	G	А	C	А	<u>C</u>	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	Τ	G	А	Т	А	Т
Seq 2	G	А	Т	1	G	G	Ţ	G	А	C	A	Т	0	G (	G	Т	A	G	А	T	А	<u>C</u>	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	A	G	А	Т	А	Т
Seq 3	G	A	Т		G	G	Τ	G	А	Τ	A	Т	0	G (	G	Т	G	G	А	<u>C</u>	А	<u>C</u>	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	G	G	А	Т	А	Т
Seq 4	G	А	Т		G	G	Ι	G	А	I	A	Т	C	a (	G	Т	A	G	А	Ι	А	Ι	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	A	G	А	Т	А	Т
Seq 5	G	А	Т	. (	G	G	I	G	А	Ţ	A	Т	G	à (	G	Т	<u>G</u>	G	А	<u>C</u>	А	<u>C</u>	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	G	G	А	Т	А	Т
Seq 6	G	А	Т		G	G	<u>C</u>	G	А	C	A	Т	Ċ	à (	G	Т	Ι	G	А	I	А	I	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	Ι	G	А	Т	А	Т
Seq 7	G	А	Т	(	G	G	Τ	G	А	Ţ	A	Т	C	à (	G	Т	G	G	А	<u>C</u>	А	<u>C</u>	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	G	G	А	Т	А	Т
Seq 8	G	А	Т		G	G	I	G	А	C	A	Т	C	à (	G	Т	A	G	А	Τ	А	<u>C</u>	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	A	G	А	Т	А	Т
Seq 9	G	А	Т	1	G	G	I	G	А	Ţ	A	Т	C	à (	G	Т	A	G	А	Ι	А	<u>C</u>	G	А	Т	G	G	Т	G	А	Т	А	Т	G	G	Т	A	G	А	Т	А	Т
Seq 10	G	А	Т		G	G	Ţ	G	А	I	A	T	0	G (	G	Т	<u>G</u>	G	А	I	А	<u>C</u>	G	А	Т	G	G	Т	G	А	Τ	А	Τ	G	G	Т	G	G	А	Τ	А	Т
Consensus	G	А	Т	. (	G	G	Y	G	А	Y	A	Т	C	à (	G	Т	D	G	А	Y	А	Y	G	А	Т	G	G	Τ	G	А	Т	А	Т	G	G	Т	D	G	А	Т	А	Т
	75	%	hor	nc	lo	gy c	ove	r 20	) ba	se	S												95	%	nomology over 20 b						logy over 20 bases											
	48	рс	ssi	bl	e p	rin	ner	cor	mbi	nat	tion	s											3	<b>3</b> possible primer combinations																		

- Sufficient information is retained for genotyping equivalent to native (4Base) genomic assays
- No loss of clinical specificity is observed by this base conversion
- e.g. HPV clinical trial showed superior performance vs. Digene assay in reducing false positives (J. Clin. Virol. 42:22-6. 2008)
- 3Base<sup>™</sup> delivers greater Sensitivity and Specificity, in a rapid assay



## Advantages of 3Base<sup>™</sup> Technology

#### Patient

- Patients receive more accurate test results
- Faster turn around time: 4-5 hours vs. 4-5 days under traditional methods
- Improved efficacy and breadth of infection detection leading to improved patient experience
- Saves lives

## Pathology Groups / Hospitals

- Cost savings due to decreased time spent evaluating samples
- Delivers greater sensitivity and specificity
- More results per patient specimen
- Reduces complexity in molecular testing
- Common workflow between tests
- Compatible with existing equipment i.e. no CAPEX requirement
- Point of differentiation

Significant benefits to the health system: minimise work, maximise results and drives value

#### Government

- Reduces hospital stays through more effective infection detection
- Fast turnaround time allows rapid detection and reduces spread of infectious diseases
- Reduced sick leave for nursing staff
- Reduces repeat doctor visits





## EasyScreen<sup>™</sup> Testing Kits

- First products to market:
  - 22 gastroenteritis pathogens including viral, bacterial and protozoan
  - 15 common respiratory infections
  - 12 common sexually transmitted infections
- Being adopted by major hospitals and pathology laboratories for detection of infectious diseases
- Deliver a wider array of highly specific results in 4-5 hours that would traditionally take 4-5 days
- Works on existing equipment found in any diagnostic laboratory
- A 1ml product volume is sufficient for 50 individual tests, driving an attractive and operationally leveraged business model
- Scalable manufacturing not limiting growth



# Case Study: St Vincent's Hospital Evaluation Study on Gastroenteritis

- Powerful evidence of efficacy

- 221 patient samples compared to traditional culture, microscopy and antibody based tests
- Results in 4 hours, compared to up to 120 hours for traditional
- Identified 44 infections that existing testing missed – 83% more than traditional testing
- Missed infections have substantial downstream consequences, such as closing down of wards (e.g Norovirus group II)

Pathogen	Conventional Methods*	EasyScreen™
Campylobacter	7	9
Salmonella	8	9
Shigella	5	6
C. Difficile	3	7
Yersinia	-	1
Cryptosporidium	-	1
Giardia	9	12
Dientamoeba fragalis	4	20
Blastocystis hominis	16	21
Entamoeba histolytica	1	1
Norovirus group 2	-	7
Adenovirus	-	1
Adenovirus 40/41	-	1
Sapovirus	-	1
Total	53	97

# 16

## Case Study: Evaluation Study on STI Detection Kit - Results from 846 Specimens



•	846 patient samples compared to	Pathogen detected	EasyScreen™	Hospital Traditional
	current testing, includes culture, and	C. trachomatis	48	31
	other molecular tests	N. gonorrhoeae	24	27
		LGV	1	1*
	Identified 503 infections that were	M. genetalium	10	Not tested
	missed with current testing	T. vaginalis	8	4
	methods – almost 3 times more	Ureaplasma spp.	296	Not tested
		Candida spp.	153	95
		M. hominis	71	Not tested
		S. agalactiae	98	51
		T. pallidum	2	2, Confirmed by reference lab
		HSV-1	32	25
		HSV-2	19	15
		Total	762	259

\* Confirmed by sequencing



# EasyScreen<sup>™</sup> Products in Development

- Product expansion will drive revenue and market share growth
- Product development pipeline includes tests for:
  - 2<sup>nd</sup> generation respiratory virus
  - Atypical pneumonia
  - Meningitis
- Additional products being readied for sale:
  - Antibiotic resistance panel
  - Flavivirus (including Chikungunya, Zika, Dengue, West Nile, Yellow Fever etc.)





# Global Growth Strategy and Commercial Progress








## **Growing Global Molecular Diagnostics Market**


- Molecular Diestimatedics (MDx) Market estimated to be US\$7.6B in 2017 representing 11% of the overall *in vitro* Diagnostics (IVD) market of \$US69B
- MDx market forecast to grow at an above system CAGR of 9.3% exceeding overall IVD market growth as MDx techniques replace traditional diagnostics



Breakdown of US\$69B Global

Source: www.mddionline.com/article/global-vitro-diagnostics-market-grow-691-billion-2017






Source: www.marketsandmarkets.com/PressReleases/molecular-diagnostic.asp and www.researchbeam.com/in-vitro-diagnostic-ivd-market

MDx growth expected to drive IVD market demand



## Large Addressable Markets


- GSS' current diagnostics products and pipeline products account for >50% of microbiology/ virology diagnostics segment
- This total addressable market was \$US1.1B in 2012 and estimated to be worth US\$2.1B by 2017





# Regulatory Approvals Now Secured in Large Portion of Global Market - Driving Revenue

- Full regulatory approval for ~22% of the global market in Gastroenteritis testing, with partial approval (Clinical Concentrators, Analyte Specific Reagents) in the USA
- Validation of company strategy with revenues ramping quickly following approvals (see Australia); European & North American revenues expected to contribute in FY17
- Further molecular diagnostic approvals sought for new products in key global markets, driving further revenue in other product categories driving shareholder value



2017 Estimate MDx Market Size by Region (USD)


Source: World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) Kalorama Information, Published: 1/9/2013, page 94.





## Significant Offshore Opportunity

- Strong revenue growth in Australia validates commercial potential of products in offshore markets
- Full regulatory approval for ~22% of the global market (Australia and Europe) Enteric products have full CE-IVD approval in Europe which is 10-20x Australian market
- Specialist clinical sales of Enteric ASR tests into North America commencing FY17
- Specialist respiratory sales commenced in Australia (~20% of FY16 revenue) with imminent availability in the US
- Multiple products/jurisdictions de-risking commercialisation





## **Global Growth Strategy**

- Focus on regions with regulatory approvals
  - Australia, Europe and US = >80% of world market
- Extend footprint in both Europe and US
  - Europe has unique testing and reimbursement strategies local knowledge is critical
  - Full distributor model in select countries, with local support
  - US growth via direct sales and support
- Realise early revenue from specialist products (e.g. ASRs in the US)
  - Larger revenues to follow with additional approvals
  - Expand product range and complete regulatory approvals for new products
  - Prepare first products for FDA approval to achieve full regulatory approvals





# **Commercialisation Progress – Australia**

- Major hospital and pathology group customers including St. Vincent's Sydney and Australian Clinical Labs
- New Sales and Marketing Director appointment to support growth
- Two new products to be released
  - Australia forms base for EU and US approvals and release
  - Product expansion will drive revenue and market share growth
- Dedicated R&D labs and network of clinical partners driving new product development:
  - 5 *EasyScreen*<sup>™</sup> products for Gastroenteritis have TGA approval
  - 2 more *EasyScreen*<sup>™</sup> kits are being validated for TGA approval





## **Commercialisation Progress - Europe**

- Addressable market of ~US\$435M
- Western Europe = ~20% global molecular diagnostics market
- Expanding team to work with European Director and Distributors
- Trials underway and more planned
- Full EU regulatory approval for complete enteric suite allows unrestricted sales in 31 countries with a market estimated at \$86m per year








## **Commercialisation Progress – North America**

- Up to ~US\$1,265M addressable market
- US = 50-60% global molecular diagnostics market
- Analyte Specific Reagents (specialist sales) launched at largest US microbiology conference
- Allows 3Base<sup>™</sup> sales to thousands of CLIA-certified laboratories
- Trials planned to commence in current quarter
- 3base<sup>™</sup> patent approval in US where focus is on completing scientific validation for FDA product approval
- First products preparing for full FDA approval, allowing unrestricted sales in US



## Outlook



## Further strong growth expected in FY18

- Launch of regulatory approved products into Australia and EU
- ASR product trials planned for the US
- Alliances made with leading KOL and health laboratories

## **Progressing significant offshore opportunities**

- Expect to capture a similar % of sales in Europe, following Australian growth trajectory addressable market of ~US\$435M
- Commence sales of ASRs into the US market addressable market up to ~US\$1265M
- Continuing FDA work for full regulatory products

## **Driving shareholder value**

- Accelerate revenues through distribution and direct sales activities globally
- Accelerate R&D and approval activates globally, unlocking further revenues and strategic value within molecular test portfolio



## **Contact:**

John Melki Chief Executive Officer john@geneticsignatures.com

www.geneticsignatures.com